Atossa Genetics (NASDQ: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions.
Visit our YouTube channel to learn more about Atossa Genetics.
Atossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Oral Endoxifen Wednesday, October 25, 2017 at 10 am EDT
Atossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa’s Microcatheter Technology
Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR-T) Program in Breast Cancer
More Press Releases
Learn more about Atossa Genetics
Learn more about our programs
Contact Atossa Genetics today!